엔케이젠바이오텍코리아 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by NKGenBiotech,Inc., was filed 10 Jul 2025.
엔케이젠바이오텍코리아: what insiders have been doing
This page follows insider dealings at 엔케이젠바이오텍코리아 as filed with DART (FSS), a company from the Health Care sector. In the past year (2 November 2025 to 2 November 2026), 1 filing came from 1 insider.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
There has been no open-market purchase by an insider of 엔케이젠바이오텍코리아 for at least a year.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 1 filing here. Our records for 엔케이젠바이오텍코리아 go back to 2021, with 33 purchases and 5 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 0KRXDART:20260422000699
- ●Executives0DART
- 46,400,000 sharesShareKRXDART:20250710000568Canonical exit: 8 Oct 2025 (T+90)
- 46,402,631 sharesKRXDART:20250710000546Canonical exit: 24 Sept 2025 (T+90)
- 9,869 sharesShareKRXDART:20250710000387
- 5,539,985 sharesKRXDART:20250710000269
- 46,400,000 shares@ ₩500.00100.0% of flowShareKRXDART:20250702000485Canonical exit: 24 Sept 2025 (T+90)
- 9,421,000 shares@ ₩3,662.9338100.0% of flowShareKRXDART:20240206000064
- 24,925 sharesShareKRXDART:20240205000264Canonical exit: 9 Apr 2024 (T+90)
- 80,720 shares@ ₩2,046.2418100.0% of flowShareKRXDART:20240205000380
- 49,850 shares@ ₩3,687.3869100.0% of flowShareKRXDART:20240205000279
- 4,713,209 sharesShareKRXDART:20240110000688Canonical exit: 9 Apr 2024 (T+90)
- 40,360 sharesShareKRXDART:20240110000822Canonical exit: 9 Apr 2024 (T+90)
- 6,241,092 sharesKRXDART:20240110000785Canonical exit: 9 Apr 2024 (T+90)
- 6,250 sharesShareKRXDART:20240110000771Canonical exit: 9 Apr 2024 (T+90)
- 7,017,314 sharesKRXDART:20231228000678Canonical exit: 26 Mar 2024 (T+90)
- ShareKRXDART:20231228000691
- 7,017,314 sharesKRXDART:20231220000522Canonical exit: 19 Mar 2024 (T+90)
- 7,017,314 sharesKRXDART:20231122000279Canonical exit: 18 Feb 2024 (T+90)
- 7,017,314 sharesKRXDART:20231006000509Canonical exit: 25 Dec 2023 (T+90)
- 7,017,314 sharesKRXDART:20230911000336Canonical exit: 3 Dec 2023 (T+90)
- 7,017,314 sharesKRXDART:20230817000256Canonical exit: 8 Nov 2023 (T+90)
- 7,017,314 sharesKRXDART:20230706000276Canonical exit: 1 Oct 2023 (T+90)
- 7,017,314 sharesKRXDART:20230609000399Canonical exit: 7 Sept 2023 (T+90)
- 7,017,314 sharesKRXDART:20230602000398Canonical exit: 29 Aug 2023 (T+90)
25 of 52 declarations
About 엔케이젠바이오텍코리아
NK Gen Biotech Korea is a company in the health and pharmaceutical sector, listed on the XKRX market. It specializes in the development of biopharmaceutical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
